Initial results indicated that this phenomenon may be related to the interplay between EGFR and the immune environment, such as weakening immunogenicity through low PD-L1 expression, low CD8+ tumor-infiltrating lymphocytes, and low tumor mutational burden (TMB); however, the specific mechanism is unclear (7, 16). The gene discussed is EGFR; the disease is neoplasm.